You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 1
  • 4CPS-180 Sacituzumab-govitecan in metastatic triple-negative breast cancer: comparison of our data to the ascent trial after 2 years of experience

Article info

Article menu

Download PDFPDF

Section 4: Clinical pharmacy services
4CPS-180 Sacituzumab-govitecan in metastatic triple-negative breast cancer: comparison of our data to the ascent trial after 2 years of experience
Free

Authors

Citation

Dho L, Maire A, Levenbruck C, et al
4CPS-180 Sacituzumab-govitecan in metastatic triple-negative breast cancer: comparison of our data to the ascent trial after 2 years of experience
European Journal of Hospital Pharmacy 2024;31:A138.

Publication history

  • First published March 20, 2024.
Online issue publication 
March 20, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.